Evaluation of Impact of Voiding Posture on Uroflowmetry Parameters in Men

PURPOSE: To evaluate the impact of voiding position on uroflowmetry parameters and to assess its potential clinical implications. MATERIALS AND METHODS: We conducted a prospective study from 2013 to 2015 and included men between 18 and 77 years old who were either healthy volunteers with an International Prostate Symptom Score (IPSS) ≤7 or men with benign prostate enlargement that were on alpha-blocker medication and had an IPSS <10. Participants underwent uroflowmetry and post-void residual urine (PVRU) measurements twice, once in a sitting position and once in a standing position. The participants were divided into 4 groups based on age (35 years or younger, 36 to 50 years, 51 to 60 years, and older than 60 years). RESULTS: A total of 740 men with a mean age of 40.35 years were evaluated. There was no significant difference in uroflowmetry parameters until the age of 50 years between the voiding positions. However, in those older than 50 years, PVRU volume was significantly lower in the sitting position than the standing position, whereas voiding time was significantly higher in the sitting position than the standing position. Other uroflowmetry parameters, including maximal and average urine flow rates, were non-significant. CONCLUSIONS: The voiding position plays an important role in the uroflowmetry parameters of elderly men. Voiding in the sitting position was found to be optimal for elderly men, whereas the role of the voiding position in healthy young men could not be determined. More research is needed to further study this issue.

Andropause in Indian men: a preliminary cross-sectional study

The purpose of this study was to determine the frequency of androgen decline in the aging male [ADAM] in a group of Indian men working in the health sector. A free medical health checkup camp was organized for the male workers aged between 40 and 60 years employed in surgical departments of our hospital. Of 180 listed male workers, 170 attended this camp 157 eligible men participated in the study. After clinical history and systemic inquiry, the participants were requested to complete the Saint Louis University's ADAM questionnaire, and their serum levels of free and total testosterone were measured. Symptomatic andropause was found in 106 men [67.5%] on the basis of their responses to the questionnaire, of whom 41 [38.7%] had low serum free testosterone levels and 32 [30.2%] had low serum levels of total testosterone. Fifty-one men were asymptomatic according to the questionnaire and in this group, 11 [21.6%] had low serum free testosterone levels and 6 [11.8%] of these had low total testosterone levels. The frequency of andropause was 33.1% on the basis of low serum free testosterone levels and it was 26.1% when both symptoms and low serum free testosterone levels were taken into account. In our study, the high frequency of symptoms related to ADAM was unusual. This might be due to the nature of the questionnaire itself. Serum free testosterone measurement may be a better single test for diagnosis of hypogonadism than serum total testosterone measurement